Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Announces Positive Results from Phase 3 Trial of TO-208 for Molluscum Treatment in Japan

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leading dermatology therapeutics provider, has shared promising top-line results from the Phase 3 trial of TO-208 for molluscum contagiosum (“molluscum”) …

Verrica Pharmaceuticals Announces Positive Results from Phase 3 Trial of TO-208 for Molluscum Treatment in Japan Read More



Philips’ DreamStation 2 CPAP Machines

FDA Issues Safety Alert on Philips Respironics’ DreamStation 2 CPAP Machines Due to Overheating Risks

The U.S. Food and Drug Administration (FDA) has recently issued an alert for patients and healthcare providers regarding a safety issue involving the DreamStation 2 Continuous Positive Airway Pressure (CPAP) …

FDA Issues Safety Alert on Philips Respironics’ DreamStation 2 CPAP Machines Due to Overheating Risks Read More

Trevena

Trevena’s Investigator-Led RELIEVE Study Accepted for Presentation at 2024 American Burn Association Meeting

CHESTERBROOK, PA — Biopharmaceutical company Trevena, Inc. (Nasdaq: TRVN), known for its innovative work in developing and commercializing novel medicines for central nervous system disorders, recently announced the acceptance of …

Trevena’s Investigator-Led RELIEVE Study Accepted for Presentation at 2024 American Burn Association Meeting Read More